NCT04980404View on ClinicalTrials.gov

Inqovi Maintenance Therapy in Myeloid Neoplasms

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 17, 2021

Primary Completion Date

August 24, 2023

Study Completion Date

November 30, 2026

Conditions
Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaStem Cell Leukemia
Interventions
DRUG

Inqovi

Tablet combination of drugs decitabine and cedazuridine, given orally.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Taiho Oncology, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT04980404 - Inqovi Maintenance Therapy in Myeloid Neoplasms | Biotech Hunter | Biotech Hunter